AlphaMadera's AlphaVal page computes Merck & Co., Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag MRK as undervalued, fairly valued, or overvalued.

What is Merck & Co., Inc.'s fair value?

Fair value for MRK is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value MRK?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from MRK's most recent reported fundamentals.

MRK - Merck & Co., Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $129.31 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

Stable Earnings Power 80% confidence

Primary model: P/Adj-EPS × Normalized Multiple

Valuation Signal Fair Value Mild

Trading 1.9% below fair value

Current Price $122.41

Bear Case $106.95 12.6% downside ($106.95 - $122.41) / $122.41 = -12.6% $8.22 × 13x P/E

Fair Value $124.77 1.9% upside ($124.77 - $122.41) / $122.41 = 1.9% $8.22 × 15x P/E

Bull Case $142.60 16.5% upside ($142.60 - $122.41) / $122.41 = 16.5% $8.22 × 17x P/E

Adjust Assumptions

P/E Multiple

14.9x

Adjusted EPS

8.22$

Key Value Driver

Normalized P/E multiple (15x base case)

Implied Market Multiple 14.9x

Plain-Language Summary

Our base-case estimate uses a valuation based on adjusted earnings per share and a normalized price-to-earnings multiple. We then blend that result with the average analyst price target of $129.31 from 37 analysts, using a 30% weight on analyst consensus. That produces an estimated intrinsic value of $124.77 per share.

Warnings

ℹ Dividend-based valuation: $95.62 (below our primary estimate by 22%). Large gaps may signal the dividend doesn't reflect full earning power.

Key Risks

Growth DCF inappropriate — terminal value assumptions dominate
EV/EBITDA misleading for regulated businesses where capex is mandated
Regulatory risk is a fat tail not visible in normal multiples